Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Solange Peters, Alex A. Adjei, Cesare Gridelli et al. · Annals of Oncology · 2012
Cited by 930 works. doi:10.1093/annonc/mds226 Open-access PDF
Authors
References
- Global cancer statistics
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma